Orforglipron Weight Loss: What the Clinical Trials Actually Showed

If you’re searching “orforglipron weight loss,” you want one thing: real numbers from real trials, not marketing language. Orforglipron — sold as Foundayo — is the first oral, once-daily small-molecule GLP-1 receptor agonist FDA-approved for chronic weight management. Here’s exactly what its phase 3 trials reported, straight from the FDA label and Eli Lilly’s own published results, dose by dose.

This is educational, not medical advice

Nothing here is a promise of what you personally will lose, and it isn’t a recommendation for or against any specific dose. Weight-loss trial results are averages across hundreds of participants — individual results vary widely and depend on your starting weight, the dose you reach, how consistently you take it, and whether you pair it with a reduced-calorie diet and increased physical activity, which is how Foundayo is FDA-approved to be used. Only a prescriber can tell you what to expect for your situation.

Where these numbers come from

Foundayo’s efficacy data comes from two phase 3 trials, both lasting 72 weeks (about a year and a half):

• ATTAIN-1 (NCT05869903): adults with obesity, or overweight plus at least one weight-related condition, without type 2 diabetes.
• ATTAIN-2 (NCT05872620): adults with obesity or overweight and type 2 diabetes.

Both trials compared orforglipron at three doses — 5.5 mg, 9 mg, and 17.2 mg once daily — against placebo, on top of a reduced-calorie diet and increased physical activity. The results below are drawn from Table 6 of the FDA-approved FOUNDAYO label and Eli Lilly’s official approval announcement.

Orforglipron weight loss results: ATTAIN-1 (without diabetes)

At week 72, counting all randomized participants regardless of whether they stayed on treatment the full time, the FDA label reports mean percent change in body weight:

• Placebo: -2.1%
• Orforglipron 5.5 mg: -7.4%
• Orforglipron 9 mg: -8.3%
• Orforglipron 17.2 mg: -11.1%

Eli Lilly’s own announcement of the results frames the highest-dose figure in pounds too: participants taking Foundayo, regardless of whether they completed the trial, lost an average of 25 pounds (11.1%), compared to 5.3 pounds (2.1%) with placebo. Among the smaller group who stayed on treatment as directed at the 17.2 mg dose, the average was higher — 27.3 pounds (12.4%), versus 2.2 pounds (0.9%) with placebo. Both figures are real and both are published; they’re just answering slightly different questions (see the FAQ below on why two numbers exist for the same dose).

Orforglipron weight loss results: ATTAIN-2 (with type 2 diabetes)

The second pivotal trial enrolled participants with type 2 diabetes, and the FDA label reports smaller average losses at week 72:

• Placebo: -2.5%
• Orforglipron 5.5 mg: -5.1%
• Orforglipron 9 mg: -7%
• Orforglipron 17.2 mg: -9.6%

Smaller weight-loss percentages in participants with type 2 diabetes versus those without is a pattern that shows up across the GLP-1 drug class, not something unique to orforglipron.

The pattern to notice: in both trials, weight loss increased with dose, and the trial without diabetes showed larger average losses than the trial with diabetes. No trial reported a single “orforglipron weight loss percentage” — the real answer is a range, by dose and by population.

How the dose you reach affects the number

Foundayo is titrated slowly, not started at a high dose. The label’s titration schedule moves from 0.8 mg up to 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and finally 17.2 mg, with at least 30 days at each step before moving up. Our Foundayo dosing guide covers the full schedule in detail.

The trial results above are grouped by the highest dose reached (5.5 mg, 9 mg, or 17.2 mg), and the pattern is consistent: higher doses produced larger average weight loss in both trials. That also means the 72-week trial figures reflect months of gradual titration, not weight lost quickly at a starting dose — someone just beginning treatment shouldn’t expect the 17.2 mg results in the first weeks.

What “individual results vary” actually means here

Trial averages hide a wide spread of individual outcomes. Some participants lost significantly more than the average at their dose; others lost less, and some didn’t respond meaningfully at all. Whether someone reaches the highest studied dose, how consistently they take it, and whether they combine it with the reduced-calorie diet and physical activity the trials were built around, all affect where an individual lands relative to the group average. If side effects during titration are part of what’s shaping your expectations, our orforglipron side effects guide covers what the same trials reported on that front.

How orforglipron works, briefly

Orforglipron is a once-daily, small-molecule (non-peptide) oral GLP-1 receptor agonist — a different chemical structure than injectable GLP-1s like semaglutide or tirzepatide, though it acts on the same receptor pathway. In plain terms, it’s associated with reduced appetite and “food noise,” which is the mechanism behind the weight loss measured in these trials. That mechanism is also part of why cost and dosing look different from injectables; our orforglipron price guide covers what it costs by dose and insurance situation.

Where to check the primary data yourself

Because this is exactly the kind of number worth verifying rather than taking on faith, the primary sources are public:

• The FDA-approved FOUNDAYO label (via DailyMed) has the full Table 6 with both trials, all three doses, and confidence intervals.
• Eli Lilly’s official approval announcement covers the ATTAIN-1 headline figures in both percentage and pounds.
• The ATTAIN-1 and ATTAIN-2 study records on ClinicalTrials.gov have the underlying trial design and population details.

Reading the label’s Table 6 directly is worth doing if you want the confidence intervals and diabetes-status breakdown in full, rather than a summary.